Cargando…
Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression
Cancer stem cells (CSCs) niche in the tumor microenvironment is responsible for cancer recurrence and therapy failure. To better understand its molecular and biological involvement in hepatocellular carcinoma (HCC) progression, one can design more effective therapies and tailored then to individual...
Autores principales: | Rani, Bhavna, Malfettone, Andrea, Dituri, Francesco, Soukupova, Jitka, Lupo, Luigi, Mancarella, Serena, Fabregat, Isabel, Giannelli, Gianluigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841307/ https://www.ncbi.nlm.nih.gov/pubmed/29515105 http://dx.doi.org/10.1038/s41419-018-0384-5 |
Ejemplares similares
-
NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017) -
Epithelial–Mesenchymal Transition (EMT) Induced by TGF-β in Hepatocellular Carcinoma Cells Reprograms Lipid Metabolism
por: Soukupova, Jitka, et al.
Publicado: (2021) -
Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma
por: Dituri, Francesco, et al.
Publicado: (2022) -
Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma
por: Chaoul, Nada, et al.
Publicado: (2020) -
New Insights into the Crossroads between EMT and Stemness in the Context of Cancer
por: Fabregat, Isabel, et al.
Publicado: (2016)